Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(8):569; doi:10.1093/jnci/96.8.569
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2004 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Cancer Stem Cells as Targets for Anticancer Agents

Drugs directed at cancer-specific targets, such as imatinib mesylate in chronic myeloid leukemia, have the potential to favorably influence patient outcomes by decreasing toxicity and improving disease control. However, recent laboratory and clinical data raise questions about whether new anticancer agents will effectively target relevant subsets of cancer cells. In a commentary, Jones et al. (p. 583) discuss the biologic distinction between cancer stem cells—the rare population of cells that give rise to malignancies—and the differentiated cells that characterize the disease. They note that therapies that target mature cancer cells are unlikely to produce long-term remissions . . . [Full Text of this Article]

Chlamydia psittaci and Ocular Adnexal Lymphomas

Implementation of a Smoking Cessation Intervention

Projected Cost-Effectiveness and Benefits of an HPV Vaccine

Lower-Category Benign Breast Disease and Breast Cancer Risk

Tamoxifen and Breast Density in High-Risk Women